Yan Liu
Last active: 6/14/2013

Profile

I joined Dr. Richmond lab in 2010 and focus on melanoma preclinical studies.

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A (2013) EMBO Mol Med 5(1): 149-66
    › Primary publication · 23180582 (PubMed) · PMC3569660 (PubMed Central)
  2. XZH-5 inhibits STAT3 phosphorylation and enhances the cytotoxicity of chemotherapeutic drugs in human breast and pancreatic cancer cells. Liu A, Liu Y, Jin Z, Hu Q, Lin L, Jou D, Yang J, Xu Z, Wang H, Li C, Lin J (2012) PLoS One 7(10): e46624
    › Primary publication · 23056374 (PubMed) · PMC3463519 (PubMed Central)
  3. RAF265 inhibits the growth of advanced human melanoma tumors. Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2012) Clin Cancer Res 18(8): 2184-98
    › Primary publication · 22351689 (PubMed) · PMC3724517 (PubMed Central)
  4. LLL12 inhibits endogenous and exogenous interleukin-6-induced STAT3 phosphorylation in human pancreatic cancer cells. Liu A, Liu Y, Li PK, Li C, Lin J (2011) Anticancer Res 31(6): 2029-35
    › Primary publication · 21737619 (PubMed) · PMC4288000 (PubMed Central)
  5. Targeting colon cancer stem cells using a new curcumin analogue, GO-Y030. Lin L, Liu Y, Li H, Li PK, Fuchs J, Shibata H, Iwabuchi Y, Lin J (2011) Br J Cancer 105(2): 212-20
    › Primary publication · 21694723 (PubMed) · PMC3142799 (PubMed Central)
  6. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Liu Y, Liu A, Li H, Li C, Lin J (2011) Cancer Prev Res (Phila) 4(8): 1296-305
    › Primary publication · 21490132 (PubMed)
  7. Novel small molecule, XZH-5, inhibits constitutive and interleukin-6-induced STAT3 phosphorylation in human rhabdomyosarcoma cells. Liu A, Liu Y, Xu Z, Yu W, Wang H, Li C, Lin J (2011) Cancer Sci 102(7): 1381-7
    › Primary publication · 21435102 (PubMed)
  8. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. Liu Y, Lin J (2011) Future Oncol 7(2): 161-4
    › Primary publication · 21345134 (PubMed)
  9. XZH-5 inhibits STAT3 phosphorylation and causes apoptosis in human hepatocellular carcinoma cells. Liu Y, Liu A, Xu Z, Yu W, Wang H, Li C, Lin J (2011) Apoptosis 16(5): 502-10
    › Primary publication · 21311975 (PubMed)
  10. STAT3 as a Therapeutic Target for Glioblastoma. Liu Y, Li C, Lin J (2010) Anticancer Agents Med Chem 10(7): 512-9
    › Primary publication · 20879983 (PubMed)
  11. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Liu Y, Fuchs J, Li C, Lin J (2010) Cell Cycle 9(17): 3423-7
    › Primary publication · 20818158 (PubMed)
  12. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. Liu Y, Li PK, Li C, Lin J (2010) J Biol Chem 285(35): 27429-39
    › Primary publication · 20562100 (PubMed) · PMC2930741 (PubMed Central)
  13. Regulation of G(1) arrest and apoptosis in hypoxia by PERK and GCN2-mediated eIF2alpha phosphorylation. Liu Y, László C, Liu Y, Liu W, Chen X, Evans SC, Wu S (2010) Neoplasia 12(1): 61-8
    › Primary publication · 20072654 (PubMed) · PMC2805884 (PubMed Central)
  14. Regulation of hdm2 by stress-induced hdm2alt1 in tumor and nontumorigenic cell lines correlating with p53 stability. Dias CS, Liu Y, Yau A, Westrick L, Evans SC (2006) Cancer Res 66(19): 9467-73
    › Primary publication · 17018602 (PubMed)